Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RANIA: Switching to Raltegravir + Nevirapine + Lamivudine in HIV
NCT02116660Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2014
- Primary completion
- Jul 2017
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of raltegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Merck & Co. Primary endpoint: Change From Baseline in Estimated Glomerular Filtration Rate at 48 weeks. Started Sep 2014; status: terminated.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02116660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02116660.